<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104224">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01925261</url>
  </required_header>
  <id_info>
    <org_study_id>TPX-100</org_study_id>
    <nct_id>NCT01925261</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OrthoTrophix, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OrthoTrophix, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This one-year study is designed to investigate the safety and efficacy of TPX-100, a
      23-amino acid chondrogenic peptide, delivered by intra-articular injection, in regeneration
      of knee cartilage in subjects with bilateral osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in cartilage thickness in the patello-femoral compartment as measured on standardized MRI from baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change in cartilage thickness in the patello-femoral compartment from baseline to 12 months</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>TPX-100 Cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 1 will be 20mg dose of TPX-100 in one randomized knee, compared to placebo treated knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPX-100 Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 2 will be 50mg dose of TPX-100 in one randomized knee compared to placebo treated knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPX-100 Cohort 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 3 will be 100mg dose of TPX-100 in one randomized knee compared to placebo treated knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPX-100 Cohort 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 4 will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPX-100 50mg</intervention_name>
    <arm_group_label>TPX-100 Cohort 2</arm_group_label>
    <other_name>50mg of TPX-100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPX-100 100mg</intervention_name>
    <arm_group_label>TPX-100 Cohort 3</arm_group_label>
    <other_name>100mg of TPX-100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPX-100 200mg</intervention_name>
    <arm_group_label>TPX-100 Cohort 4</arm_group_label>
    <other_name>200mg of TPX-100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPX-100 20mg</intervention_name>
    <arm_group_label>TPX-100 Cohort 1</arm_group_label>
    <other_name>20mg of TPX-100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>TPX-100 Cohort 1</arm_group_label>
    <arm_group_label>TPX-100 Cohort 2</arm_group_label>
    <arm_group_label>TPX-100 Cohort 3</arm_group_label>
    <arm_group_label>TPX-100 Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 25 and ≤ 75

          2. Patello-femoral osteoarthritis of both knees of mild to moderate severity with intact
             meniscus and ligamentous stability (cruciate and collateral ligaments)

               -  Clinically, as determined by screening questionnaire and  judgment of the
                  Principal Investigator (may be supported by imaging studies of knees); confirmed
                  by centrally read screening MRI of both knees indicating ICRS Grade 1-3, or ICRS
                  Grade 4 with only focal defects, no greater than 1 cm.

               -  Meniscus intact (MRI degenerative signal up to and including grade II
                  acceptable)

               -  Cruciate and collateral ligament stability as defined by clinical examination

          3. Able to read, understand, sign and date the subject informed consent

          4. Willingness to use only acetaminophen as the primary analgesic (pain-relieving) study
             medication. The maximum dose of acetaminophen must not exceed 4 grams/day (4000 mg
             per day).

          5. Willingness to use only hydrocodone/acetaminophen for breakthrough pain during the
             injection period (through study day 30).

          6. Willingness not to use non-steroidal anti-inflammatory drugs (NSAIDS) such as
             aspirin, ibuprofen, naproxen for the first 30 days of the study.

          7. Female subjects of child bearing potential who are sexually active (non-abstinent)
             must agree to and comply with using 2 highly effective methods of birth control (oral
             contraceptive, implant, injectable or indwelling intrauterine device, condom with
             spermicide, or sexual abstinence) while participating in the study.

        Exclusion Criteria:

          1. Contraindication to MRI, including: metallic fragments, clips or devices in the
             brain, eye, or spinal canal; implanted devices that are magnetically programmed;
             weight &gt; 300 lbs.; moderate or severe claustrophobia; previous intolerance of MRI
             procedure

          2. ICRS grade greater than Grade 3,  or Grade 4 focal defects greater than 1 cm, as
             confirmed by centrally-read screening MRI

          3. MRI evidence of inflammatory or hypertrophic synovitis

          4. Prior surgery in the knees, excluding procedures for debridement only (no
             microfracture)

          5. Joint replacement or any other knee surgery planned in the next 12 months

          6. History of rheumatoid arthritis, psoriatic arthritis, or any other autoimmune or
             infectious cause for arthritis

          7. Knee effusion &gt;2+ on the following clinical scale:

               -  Zero = No wave produced on downstroke

               -  Trace = Small wave on medial side with downstroke

               -  1+ = Larger bulge on medial side with downstroke

               -  2+ = Effusion spontaneously returns to medial side after upstroke (no downstroke
                  necessary)

               -  3+ = So much fluid that it is not possible to move the effusion out of the
                  medial aspect of the knee

          8. Last viscosupplementation (e.g. Synvisc® or similar hyaluronic acid product) injected
             into either  knee &lt; 3 months before screening

          9. Last intra-articular knee injection of corticosteroids &lt; 2 months before screening

         10. Use of any steroids (except inhaled corticosteroids for respiratory problems) during
             the previous month before screening

         11. Known hypersensitivity to TPX-100

         12. Known hypersensitivity to acetaminophen or hydrocodone

         13. History of arthroscopy in either knee in the last 3 months before screening

         14. History of septic arthritis, gout or pseudo-gout, of either knee in previous year
             before screening

         15. Clinical signs of acute meniscal tear (locking, new acute mechanical symptoms
             consistent with meniscal tear)

         16. Patellar chondrocalcinosis on X-Ray

         17. Skin problem, rash or hypersensitivity, affecting either knee at the injection site

         18. Bleeding problem, platelet or coagulation deficiency contraindicating, in the
             doctor's opinion, any intra-articular injection

         19. Active systemic infection

         20. Current treatment or treatment within the previous 2 years prior to the Screening
             Visit for any malignancy except basal cell or squamous cell carcinoma of the skin,
             unless with specific written permission is provided by the Sponsor's medical monitor

         21. Women of childbearing potential who are pregnant, nursing, or planning to become
             pregnant, and those who do not agree to remain on an acceptable method of birth
             control throughout the entire study period

         22. Participation in other clinical osteoarthritis drug studies  within one year prior to
             screening

         23. Currently taking Paclitaxel (mitotic inhibitor), and or Natalizumab (anti-integrin
             monoclonal antibody).

         24. History of significant liver disease or consumption of more than 3 alcoholic drinks a
             day. (Definition of one alcoholic drink: 12-ounces of beer, 8-ounces of malt liquor,
             5-ounces of wine, 1.5-ounces or a &quot;shot&quot; of 80-proof distilled spirits or liquor such
             as gin, rum, vodka, or whiskey).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ron Carozza, Pharm D</last_name>
    <phone>(206) 686-4644</phone>
    <email>Rcarozza@c3-research.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meghan Miller, MS</last_name>
    <phone>510-488-3827</phone>
    <email>meghan.miller@orthotrophix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medvin Research</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renne Garcia</last_name>
      <email>Renee@medvinresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Vipul Vineet</last_name>
      <email>vipul@medvinresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Samy Metyas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis Care and Research Center</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Sartore</last_name>
      <phone>858-673-4589</phone>
      <email>lynnsartore@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis Center for Musculoskeletal Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Macias</last_name>
      <phone>916-734-8538</phone>
      <email>denise.macias@ucdmc.ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Nunez</last_name>
      <phone>9167344536</phone>
      <email>andrea.nunez@ucdmc.ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nancy Lane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Hans Richard Barthel</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharyn Plunkett</last_name>
      <email>splunkett@sbcr.net</email>
    </contact>
    <investigator>
      <last_name>Hans R Barthel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>August 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>knee osteoarthritis</keyword>
  <keyword>bilateral</keyword>
  <keyword>osteoarthritis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
